Aurora Cannabis and Ethypharm Extend Role in French Medical Cannabis Trial

Aurora Cannabis and Ethypharm have been reselected by France's Direction Générale de la Santé (DGS) to supply dried medical cannabis flowers as part of the extended French medical cannabis trial, now running until March 2024. This decision solidifies their position as key players in France's ongoing exploration of medical cannabis use. The trial, initially launched in March 2021, aims to assess the therapeutic benefits and regulatory implications of cannabis in a controlled setting

Dr. Axel Gille, President of Aurora Europe, expressed satisfaction at being chosen again, emphasizing the company's commitment to advancing medical cannabis markets in Europe. "Our goal is to open the world to cannabis," Gille stated, highlighting Aurora's dedication to working closely with government officials, healthcare providers, and pharmacists to reduce stigma and expand market access

The partnership between Aurora and Ethypharm began in October 2020 under the auspices of the French National Agency for the Safety of Medicines and Health Products (ANSM). Aurora provides the cannabis and ensures compliance with EU Good Manufacturing Practices (GMP), while Ethypharm handles distribution and pharmacovigilance. This collaboration underscores the companies' shared commitment to maintaining high standards in medical cannabis production and distribution

In January 2023, the DGS issued a call for tenders to continue the supply of medical cannabis, leading to the reappointment of Aurora and Ethypharm in March. The selection ensures that patients involved in the study will continue to receive cannabis produced to stringent European standards. The trial's extension reflects France's cautious yet progressive approach to integrating cannabis into its healthcare system

Looking ahead, both companies are focused on enhancing the accessibility and perception of medical cannabis in Europe. Frédéric Arnal, General Manager of Ethypharm Laboratories, emphasized their goal to leverage cannabis in treating central nervous system disorders, particularly pain management. He expressed hope that the trial will demonstrate the potential benefits of medical cannabis for French patients, potentially paving the way for broader acceptance and use